FINWIRES · TerminalLIVE
FINWIRES

ASX:RCE

10 stories mentioning ASX:RCEUpdated 9d ago

Every FINWIRES story that references ASX:RCE, newest first.

Asia

Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy

Recce Pharmaceuticals (ASX:RCE) said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's (ASPR) new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.Its shares rose 1% in recent trading on Thursday.

ASX:RCE
Asia

Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter

Recce Pharmaceuticals (ASX:RCE) ended the June quarter with a cash balance of AU$2.9 million, according to a Tuesday filing with the Australian bourse.The company closed the March quarter with a cash balance of AU$1.7 million, an earlier filing showed.During the June quarter, Recce saw net cash outflows from operating activities of AU$2.2 million, with research and development accounting for the majority of that spend.The company's shares gained 1% in recent Tuesday trade.

ASX:RCE
Asia

Recce Pharmaceuticals Extends Share Purchase Plan Closing Date

Recce Pharmaceuticals (ASX:RCE) has extended the closing date of its share purchase plan (SPP) to Friday, providing eligible shareholders with additional time to subscribe for shares under the offer, according to a Monday Australian bourse filing.The SPP allows shareholders to acquire up to AU$30,000 worth of fully paid ordinary shares at AU$0.40 per share, with no brokerage or transaction fees applicable, the filing said.Participants will also have the opportunity to apply for free attaching options, subject to shareholder approval, which may include additional "piggyback" options upon exercise, the filing added.

ASX:RCE
Asia

ASX Preview: Australian Shares to Decline; Genesis Minerals to Acquire Vault Minerals for AU$5.274 per Share

Australian shares are expected to open with a modest decline on Tuesday as oil surged over escalating Middle East tensions.Brent crude oil futures jumped over 9% to trade around $83 per barrel after US President Donald Trump said the US would impose a 20% toll on shipping in the Strait of Hormuz. The US ​is set to reinstate a naval blockade on Iran on Tuesday.Meanwhile, US Federal Reserve governor Christopher Waller said rate increases may be needed if underlying inflation continues to signal broad price pressures.Overnight, the S&P 500, Nasdaq Composite, and Dow Jones fell 0.8%, 1.6%, and 0.3%, respectively.In the macroeconomy, the ANZ-Roy Morgan Australian Consumer Confidence rose 0.6 points in the week ended July 10 to 75.3 points. The four-week moving average lifted 1.1 points to 74.7 points.In corporate news, Genesis Minerals (ASX:GMD) agreed to acquire Vault Minerals (ASX:VAU) for AU$5.274 per share. Vault shareholders will receive 0.7629 new Genesis ordinary shares plus AU$0.475 in cash for each Vault share they hold.Recce Pharmaceuticals (ASX:RCE) said the Intellectual Property Office of Vietnam formally granted a Family 4 patent for its anti-infectives, expiring in 2041.Australia's benchmark index edged up 0.03% or 2.5 points on Monday to close at 8,808.50.

ASX 200ASX:GMDASX:RCEASX:VAU
Asia

Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Vietnam

Recce Pharmaceuticals (ASX:RCE) said the Intellectual Property Office of Vietnam formally granted a Family 4 patent for its anti-infectives, expiring in 2041, according to a Tuesday Australian bourse filing.The patent relates to the process for preparing the anti-infectives, as well as the use of its R327 and R529 therapy candidates, particularly in the treatment of bacterial infections and viral infections.It also relates to the administration of the anti-infectives by oral, inhalation, transdermal delivery, or by injection. They can also be delivered as an aerosol, gel, topical foam, or ointment.

ASX:RCE
Asia

Recce Pharmaceuticals to Raise AU$4 million via Share Placement; Shares Down 17%

Recce Pharmaceuticals (ASX:RCE) received firm commitments to raise AU$4 million through the placement of 10 million new shares at AU$0.40 apiece, according to a Friday filing with the Australian bourse.The company is also launching a share purchase plan to allow eligible shareholders to subscribe for up to AU$30,000 worth of new shares to raise up to a further AU$4 million on the same terms as the placement, the filing said.Funds will be used to bolster the balance sheet for commercial licensing with a Middle Eastern pharmaceutical firm, and fund clinical trials and Investigational New Drug enabling activities, per the filing.Shares fell 17% in morning trade on Friday.

ASX:RCE
Asia

Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise

Recce Pharmaceuticals (ASX:RCE) requested an immediate trading halt on the Australian Securities Exchange pending an update on a proposed equity capital raising, according to a Wednesday Australian bourse filing.The company has requested that the halt remain in place until the earlier of Friday's normal trading session or release of the capital raising update, the filing added.

ASX:RCE
Asia

Recce Says HREC Approval Progresses Phase 3 Clinical Trial of Diabetic Foot Infections Treatment Candidate

Recce Pharmaceuticals (ASX:RCE) said the Human Research Ethics Committee (HREC) approved a protocol amendment to its phase two clinical trial of Recce 327 topical gel treatment candidate for diabetic foot infections, advancing the study to a pivotal phase three clinical trial, according to a Monday Australian bourse filing.A pivotal phase three trial is considered a registrational study designed to generate the safety and efficacy data required to support regulatory approval applications. The trial has treated 18 of a potential 200 total patients and full enrollment is expected by the end of 2027.The protocol amendment expands eligibility to include moderate infection patients in addition to mild infection patients.The company said its completed phase two trial achieved a 93% primary efficacy endpoint at day 14 and 86% clinical response by day seven.Recce Pharmaceuticals' shares rose 1% in recent trading on Monday.

ASX:RCE
Asia

Recce Pharmaceuticals Enters Proposed 10-Year Exclusive Licensing Nonbinding Agreement with Middle Eastern Firm, Shares Rise 10%

Recce Pharmaceuticals (ASX:RCE) entered into a non-binding term sheet with a Middle Eastern pharmaceutical company for a proposed 10-year exclusive licensing arrangement covering the commercial sales and distribution of Recce's proprietary R327 topical gel for the treatment of diabetic foot infections, according to a Wednesday Australian bourse filing.The agreement covers Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Bahrain, Qatar, Iraq, Egypt, Algeria, and Morocco. Recce will be responsible for the manufacture and supply of the R327 topical gel.The agreement is expected to include an upfront signing fee, together with milestone payments totalling up to $3.5 million. Recce is also expected to receive 30% of the net selling price, with an additional 6% annual royalty on net sales of over $50 million per year. The proposed selling price is $1,500 per treatment, subject to agreement with the regulatory authority in Saudi Arabia.The parties are collaborating to finalize and execute a definitive agreement.Its shares rose 10% in recent trading on Wednesday.

ASX:RCE
Asia

Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site

Recce Pharmaceuticals (ASX:RCE) said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.The firm's shares rose 2% in recent trading on Tuesday.

ASX:RCE

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:RCE in your portfolio
WheelAI
WheelAI
Analyze ASX:RCE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:RCE